Article Type

Original Study


Objective The aim of this work was to study the correlation between serum free triiodothyronine (FT3) level and inflammation in hemodialysis (HD) patients. Background End-stage renal disease (ESRD) is associated with a markedly increased mortality risk, with cardiovascular diseases being the most common cause of death. FT3 is a marker of comorbidity in ESRD and in many acute and chronic diseases. Patients and methods This case–control study included 30 patients with ESRD on maintenance HD (17 men and 13 women) (mean age 43.93 ± 12.12 years), 20 patients with chronic kidney disease not on HD (12 male and eight female) (mean age 42.4 ± 12.42 years), and 20 healthy controls (12 male and eight female) (mean age 37.25 ± 10.52). Serum FT3 and thyroid-stimulating hormone concentrations were determined. C-reactive protein (CRP) was used as a marker of inflammation. Demographic data and laboratory values were evaluated. Results Our results showed a significantly lower serum FT3 level in the HD group compared with the chronic kidney disease and control groups (P < 0.001). Moreover, it showed nonsignificant differences in the serum thyroid-stimulating hormone levels between all groups (P = 0.765). In the HD group, there was a significant negative correlation between serum FT3 and CRP level (ρ=−0.83; P= 0.001), between serum CRP and albumin levels (ρ=−0.37; P= 0.004), and between serum FT3 level and number of dialysis years of patients (ρ=−0.455; P= 0.012). In contrast, a positive correlation was noticed between serum CRP levels and number of dialysis years of patients (ρ=0.371; P= 0.044). Conclusion The results of this study indicate a significant inverse correlation between CRP and plasma T3 circulating levels in patients undergoing HD. This investigation suggested that inflammation might be involved in the low T3 syndrome in HD patients. Thus, we suggest that FT3 levels can be used as a marker for inflammation in ESRD patients.